#United States #New York #Levi Korsinsky #MLTX #MoonLake Immunotherapeutics

Class Action Lawsuit Filed Against MoonLake Immunotherapeutics

On December 5, 2025, Levi & Korsinsky, LLP announced the initiation of a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics (NASDAQ: MLTX). The suit aims to address alleged securities fraud that transpired between March 10, 2024, and September 29, 2025.

Allegations Against MoonLake

The complaint outlines several critical issues that investors faced. It claims that during the specified period, the company made misleading statements regarding its sole drug candidate, SLK, and its relationship with BIMZELX. Specifically, the lawsuit highlights that:

1. Shared Molecular Targets: SLK and BIMZELX share the same inflammatory cytokine targets—IL-17A and IL-17F—despite claims to the contrary.
2. Questionable Clinical Benefit: It argues that SLK’s unique Nanobody structure does not provide any clinical advantages over the traditional monoclonal antibody structure represented by BIMZELX.
3. Efficacy Claims Under Scrutiny: The suit emphasizes that the purported increased tissue penetration of SLK would not necessarily result in better clinical results.
4. Misleading Statements: Overall, the lawsuit asserts that MoonLake's positive statements regarding SLK's advantages were not founded on a reasonable basis.

What Investors Need to Know

For those affected, the law firm invites investors who experienced losses to take action by December 15, 2025, to request a role as lead plaintiff; however, participation in any potential recovery doesn't necessitate lead plaintiff status.

Claiming compensation comes at no charge to the investors involved. This opens the door for share recovery without upfront costs, which is particularly significant given the complexities of securities litigation.

Joseph E. Levi, one of the lead attorneys on the case, has encouraged anyone affected to reach out via email or phone for further assistance and to understand their legal options better.

Why Choose Levi & Korsinsky

Levi & Korsinsky has built a solid reputation over the past two decades for securing substantial financial recoveries for shareholders impacted by corporate wrongdoing. The firm's team is composed of over 70 skilled attorneys specializing in complex securities litigation, which positions them favorably to represent affected investors. They have consistently been recognized in top rankings for their expertise and success in high-stakes legal battles.

Conclusion

Investors in MoonLake Immunotherapeutics who believe they have been adversely affected during the defined period should consider their legal options carefully. The class action represents a crucial opportunity to seek justice and potential recourse against misleading corporate practices. Interested parties can find more information on how to participate in the lawsuit through Levi & Korsinsky’s online resources.

For more information and assistance, visit Levi & Korsinsky’s website or contact their New York office directly.